Pneumonia Therapeutics Market Size By Drug Class (Antibacterial Drugs, {Macrolide, Quinolones}, Antiviral Drugs, Antifungal Drugs), By Age Group (Paediatric, Adult, Geriatric), By Infection Type (Hospital-acquired Pneumonia [HAP], Community-acquired Pneumonia [CAP], Ventilator-associated Pneumonia [VAP]), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Industry Analysis Report, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast, 2020 - 2026


The pneumonia therapeutics market will be driven by substantial rise in number of ventilator-associated and community-acquired bacterial pneumonia cases and ongoing clinical trials for the advancement of vaccines and drug molecules. Pneumonia is an infection of the lungs which might infect one or both lungs and fill them up with fluid. 

It is caused by fungi, viruses, and bacteria. The disease is considered dangerous for adults, infants, those with weakened immune systems, and people suffering from other diseases as well. The treatment of pneumonia usually is dependent upon the germs that cause it. 

Bacterial pneumonia is generally treated with antibiotics. The particular antibiotic choice depends on factors like the general health of an individual, the type of medications one is using, any indication of antibiotic resistance in the local community as well the individuala??s age, and other health conditions that one might have. 

Additionally, medications to give relieve from pain and lower fever might also help during treatment. Meanwhile, in the case of fungal pneumonia, antifungal medicines are prescribed by the physicians. Thus, the market is driven by various medications available in the market for the treatment of different types of pneumonia.

Pneumonia therapeutics market is segmented in terms of drug class, age group, infection type, distribution channel, and regional landscape. 

Based on drug class, the pneumonia therapeutics market is classified into antifungal drugs, antiviral drugs, and antibacterial drugs. Antibacterial drugs are likely to witness around 8% CAGR over the forthcoming time period owing to the growing cases of bacterial pneumonia and introduction of new therapeutics.

In terms of age group, the overall pneumonia therapeutics market is bifurcated into geriatric, adult, and pediatric. Among these, pediatric segment held a market value of more than $336 million in 2019, owing to high prevalence of pneumonia in elderly population due to their weakened immunity.

With respect to infection type, the pneumonia therapeutics market is classified into ventilator-associated pneumonia (VAP), community-acquired pneumonia (CAP), and hospital-acquired pneumonia (HAP). Hospital-acquired pneumonia will witness around 7.5% CAGR over the projected time period owing to the increasing incidence of HAP in severely ill patients and prolonged hospital stays.

Based on distribution channel, the pneumonia therapeutics market is categorized into online pharmacies, retail pharmacies, and hospital pharmacies. Among these, the online pharmacies segment is likely to represent approximately 16% market share by the end of the analysis period owing to the ease in accessibility and promotional discounts offered by the online pharmacies.

From a regional frame of reference, Europe accounted for a market value of more than $375 million in 2019, attributable to favorable healthcare infrastructure in developed countries and high prevalence of pneumonia therapeutics.
Report Content
Chapter 1. Methodology
1.1. Methodology
1.2. Market definitions
1.3. Forecast parameters
1.4. Data sources
1.4.1.  Secondary
1.4.1.1.    Paid sources
1.4.1.2.    Unpaid sources
1.4.2.  Primary
Chapter 2. Executive Summary
2.1. Pneumonia therapeutics industry 360 degree synopsis, 2015 - 2026
2.1.1.  Business trends
2.1.2.  Drug class trends
2.1.3.  Age group trends
2.1.4.  Infection type trends
2.1.5.  Distribution channel trends
2.1.6.  Regional trends
Chapter 3. Pneumonia Therapeutics Industry Insights
3.1. Industry segmentation
3.2. Industry landscape, 2015 - 2026
3.3. Industry impact forces
3.3.1.  Growth drivers
3.3.1.1. Surging cases of pneumonia across the globe
3.3.1.2. Rising number of ongoing clinical trials for vaccine development and drug molecules
3.3.1.3. Increasing funding opportunities in R&D for new product development
3.3.1.4. Presence of various manufacturers in developed economies
3.3.2.  Industry pitfalls and challenges
3.3.2.1. Low treatment rates in developing economies
3.4. Growth potential analysis
3.4.1.  By drug class
3.4.2.  By age group
3.4.3.  By infection type
3.4.4.  By distribution channel
3.5. COVID-19 impact analysis
3.6. Product pipeline analysis
3.7. Porter's analysis
3.8. PESTEL Analysis
Chapter 4. Pneumonia Therapeutics Market, By Drug Class
4.1. Key segment trends
4.2. Antibacterial drugs
4.2.1.  Antibacterial drugs market, by region, 2015 - 2026, (USD Million)
4.2.2.  Macrolide
4.2.2.1.    Macrolide market, by region, 2015 - 2026, (USD Million)
4.2.3.  Quinolones
4.2.3.1.    Quinolones market, by region, 2015 - 2026, (USD Million)
4.2.4.  Others
4.2.4.1.    Others market, by region, 2015 - 2026, (USD Million)
4.3. Antiviral drugs
4.3.1.  Antiviral drugs market, by region, 2015 - 2026, (USD Million)
4.4. Antifungal drugs
4.4.1.  Antifungal drugs market, by region, 2015 - 2026, (USD Million)
Chapter 5. Pneumonia Therapeutics Market, By Age Group
5.1. Key segment trends
5.2. Pediatric
5.2.1.  Pediatric market by region, 2015 - 2026 (USD Million)
5.3. Adult
5.3.1.  Adult market, by region, 2015 - 2026, (USD Million)
5.4. Geriatric
5.4.1.  Geriatric market by region, 2015 - 2026 (USD Million)
Chapter 6. Pneumonia Therapeutics Market, By Application
6.1. Key segment trends
6.2. Pediatric
6.2.1. Pediatric pneumonia therapeutics market, by region, 2015 - 2026, (USD Million)
6.3. Adult
6.3.1. Adult pneumonia therapeutics market, by region 2015 - 2026, (USD Million)
6.4. Geriatric
6.4.1. Geriatric pneumonia therapeutics market, by region 2015 - 2026, (USD Million)
6.5. Veterinary
6.5.1. Veterinary pneumonia therapeutics market, by region 2015 - 2026, (USD Million)
Chapter 7. Pneumonia Therapeutics Market, By Infection Type
7.1. Key segment trends
7.2. Hospital-acquired pneumonia (HAP)
7.2.1.  Hospital-acquired pneumonia (HAP) market, by region, 2015 - 2026, (USD Million)
7.3. Community-acquired pneumonia (CAP)
7.3.1.  Community-acquired pneumonia (CAP) market, by region, 2015 - 2026, (USD Million)
7.4. Ventilator-associated pneumonia (VAP)
7.4.1.  Ventilator-associated pneumonia (VAP) market, by region, 2015 - 2026, (USD Million)
Chapter 8. Pneumonia Therapeutics Market, By Distribution Channel
8.1. Key segment trends
8.2. Hospital pharmacies
8.2.1.  Hospital pharmacies market, by region, 2015 - 2026, (USD Million)
8.3. Retail pharmacies
8.3.1.  Retail Pharmacies market, by region, 2015 - 2026, (USD Million)
8.4. Online pharmacies
8.4.1.  Online pharmacies market, by region, 2015 - 2026, (USD Million)
Chapter 9. Pneumonia Therapeutics Market, By Region
9.1. Key regional trends
9.2. North America
9.2.1.   North America pneumonia therapeutics market, by country, 2015 - 2026 (USD Million)
9.2.2.   North America pneumonia therapeutics market, By drug class, 2015 - 2026 (USD Million)
9.2.2.1.   North America pneumonia therapeutics market, by antibacterial drugs, 2015 - 2026 (USD Million)
9.2.3.    North America pneumonia therapeutics market, by age group, 2015 - 2026 (USD Million)
9.2.4.    North America pneumonia therapeutics market, by infection type, 2015 - 2026 (USD Million)
9.2.5.    North America pneumonia therapeutics market, by distribution channel, 2015 - 2026 (USD Million)
9.2.6.  U.S.
9.2.6.1.    U.S. pneumonia therapeutics market, by drug class, 2015 - 2026 (USD Million)
9.2.6.1.1.   U.S. pneumonia therapeutics market, by antibacterial drugs, 2015 - 2026 (USD Million)
9.2.6.2.    U.S. pneumonia therapeutics market, by age group, 2015 - 2026 (USD Million)
9.2.6.3.    U.S. pneumonia therapeutics market, by infection type, 2015 - 2026 (USD Million)
9.2.6.4.    U.S. pneumonia therapeutics market, by distribution channel, 2015 - 2026 (USD Million)
9.2.7.  Canada
9.2.7.1.    Canada pneumonia therapeutics market, by drug class, 2015 - 2026 (USD Million)
9.2.7.1.1.   Canada pneumonia therapeutics market, by antibacterial drugs, 2015 - 2026 (USD Million)
9.2.7.2.    Canada pneumonia therapeutics market, by age group, 2015 - 2026 (USD Million)
9.2.7.3.    Canada pneumonia therapeutics market, by infection type, 2015 - 2026 (USD Million)
9.2.7.4.    Canada pneumonia therapeutics market, by distribution channel, 2015 - 2026 (USD Million)
9.3. Europe
9.3.1.   Europe pneumonia therapeutics market, by country, 2015 - 2026 (USD Million)
9.3.2.   Europe pneumonia therapeutics market, by drug class, 2015 - 2026 (USD Million)
9.3.2.1.   Europe pneumonia therapeutics market, by antibacterial drugs, 2015 - 2026 (USD Million)
9.3.3.    Europe pneumonia therapeutics market, by age group, 2015 - 2026 (USD Million)
9.3.4.    Europe pneumonia therapeutics market, by infection type, 2015 - 2026 (USD Million)
9.3.5.    Europe pneumonia therapeutics market, by distribution channel, 2015 - 2026 (USD Million)
9.3.6.  Germany
9.3.6.1.    Germany pneumonia therapeutics market, by drug class, 2015 - 2026 (USD Million)
9.3.6.1.1.   Germany pneumonia therapeutics market, by antibacterial drugs, 2015 - 2026 (USD Million)
9.3.6.2.    Germany pneumonia therapeutics market, by age group, 2015 - 2026 (USD Million)
9.3.6.3.    Germany pneumonia therapeutics market, by infection type, 2015 - 2026 (USD Million)
9.3.6.4.    Germany pneumonia therapeutics market, by distribution channel, 2015 - 2026 (USD Million)
9.3.7.  UK
9.3.7.1.    UK pneumonia therapeutics market, by drug class, 2015 - 2026 (USD Million)
9.3.7.1.1.   UK pneumonia therapeutics market, by antibacterial drugs, 2015 - 2026 (USD Million)
9.3.7.2.    UK pneumonia therapeutics market, by age group, 2015 - 2026 (USD Million)
9.3.7.3.    UK pneumonia therapeutics market, by infection type, 2015 - 2026 (USD Million)
9.3.7.4.    UK pneumonia therapeutics market, by distribution channel, 2015 - 2026 (USD Million)
9.3.8.  France
9.3.8.1.    France pneumonia therapeutics market, by drug class, 2015 - 2026 (USD Million)
9.3.8.1.1.   France pneumonia therapeutics market, by antibacterial drugs, 2015 - 2026 (USD Million)
9.3.8.2.    France pneumonia therapeutics market, by age group, 2015 - 2026 (USD Million)
9.3.8.3.    France pneumonia therapeutics market, by infection type, 2015 - 2026 (USD Million)
9.3.8.4.    France pneumonia therapeutics market, by distribution channel, 2015 - 2026 (USD Million)
9.3.9.  Italy
9.3.9.1.    Italy pneumonia therapeutics market, by drug class, 2015 - 2026 (USD Million)
9.3.9.1.1.   Italy pneumonia therapeutics market, by antibacterial drugs, 2015 - 2026 (USD Million)
9.3.9.2.    Italy pneumonia therapeutics market, by age group, 2015 - 2026 (USD Million)
9.3.9.3.    Italy pneumonia therapeutics market, by infection type, 2015 - 2026 (USD Million)
9.3.9.4.    Italy pneumonia therapeutics market, by distribution channel, 2015 - 2026 (USD Million)
9.3.10.   Spain
9.3.10.1.  Spain pneumonia therapeutics market, by drug class, 2015 - 2026 (USD Million)
9.3.10.1.1. Spain pneumonia therapeutics market, by antibacterial drugs, 2015 - 2026 (USD Million)
9.3.10.2.  Spain pneumonia therapeutics market, by age group, 2015 - 2026 (USD Million)
9.3.10.3.  Spain pneumonia therapeutics market, by infection type, 2015 - 2026 (USD Million)
9.3.10.4.  Spain pneumonia therapeutics market, by distribution channel, 2015 - 2026 (USD Million)
9.3.11.   Russia
9.3.11.1.  Russia pneumonia therapeutics market, by drug class, 2015 - 2026 (USD Million)
9.3.11.1.1. Russia pneumonia therapeutics market, by antibacterial drugs, 2015 - 2026 (USD Million)
9.3.11.2.  Russia pneumonia therapeutics market, by age group, 2015 - 2026 (USD Million)
9.3.11.3.  Russia pneumonia therapeutics market, by infection type, 2015 - 2026 (USD Million)
9.3.11.4.  Russia pneumonia therapeutics market, by distribution channel, 2015 - 2026 (USD Million)
9.3.12.   Sweden
9.3.12.1.  Sweden pneumonia therapeutics market, by drug class, 2015 - 2026 (USD Million)
9.3.12.1.1. Sweden pneumonia therapeutics market, by antibacterial drugs, 2015 - 2026 (USD Million)
9.3.12.2.  Sweden pneumonia therapeutics market, by age group, 2015 - 2026 (USD Million)
9.3.12.3.  Sweden pneumonia therapeutics market, by infection type, 2015 - 2026 (USD Million)
9.3.12.4.  Sweden pneumonia therapeutics market, by distribution channel, 2015 - 2026 (USD Million)
9.3.13.   Finland
9.3.13.1.  Finland pneumonia therapeutics market, by drug class, 2015 - 2026 (USD Million)
9.3.13.1.1. Finland pneumonia therapeutics market, by antibacterial drugs, 2015 - 2026 (USD Million)
9.3.13.2.  Finland pneumonia therapeutics market, by age group, 2015 - 2026 (USD Million)
9.3.13.3.  Finland pneumonia therapeutics market, by infection type, 2015 - 2026 (USD Million)
9.3.13.4.  Finland pneumonia therapeutics market, by distribution channel, 2015 - 2026 (USD Million)
9.4. Asia Pacific
9.4.1.   Asia Pacific pneumonia therapeutics market, by country, 2015 - 2026 (USD Million)
9.4.2.   Asia Pacific pneumonia therapeutics market, by drug class, 2015 - 2026 (USD Million)
9.4.2.1.   Asia Pacific pneumonia therapeutics market, by antibacterial drugs, 2015 - 2026 (USD Million)
9.4.3.    Asia Pacific pneumonia therapeutics market, by age group, 2015 - 2026 (USD Million)
9.4.4.    Asia Pacific pneumonia therapeutics market, by infection type, 2015 - 2026 (USD Million)
9.4.5.    Asia Pacific pneumonia therapeutics market, by distribution channel, 2015 - 2026 (USD Million)
9.4.6.  Japan
9.4.6.1.    Japan pneumonia therapeutics market, by drug class, 2015 - 2026 (USD Million)
9.4.6.1.1.   Japan pneumonia therapeutics market, by antibacterial drugs, 2015 - 2026 (USD Million)
9.4.6.2.    Japan pneumonia therapeutics market, by age group, 2015 - 2026 (USD Million)
9.4.6.3.    Japan pneumonia therapeutics market, by infection type, 2015 - 2026 (USD Million)
9.4.6.4.    Japan pneumonia therapeutics market, by distribution channel, 2015 - 2026 (USD Million)
9.4.7.  China
9.4.7.1.    China pneumonia therapeutics market, by drug class, 2015 - 2026 (USD Million)
9.4.7.1.1.   China pneumonia therapeutics market, by antibacterial drugs, 2015 - 2026 (USD Million)
9.4.7.2.    China pneumonia therapeutics market, by age group, 2015 - 2026 (USD Million)
9.4.7.3.    China pneumonia therapeutics market, by infection type, 2015 - 2026 (USD Million)
9.4.7.4.    China pneumonia therapeutics market, by distribution channel, 2015 - 2026 (USD Million)
9.4.8.  India
9.4.8.1.    India pneumonia therapeutics market, by drug class, 2015 - 2026 (USD Million)
9.4.8.1.1.   India pneumonia therapeutics market, by antibacterial drugs, 2015 - 2026 (USD Million)
9.4.8.2.    India pneumonia therapeutics market, by age group, 2015 - 2026 (USD Million)
9.4.8.3.    India pneumonia therapeutics market, by infection type, 2015 - 2026 (USD Million)
9.4.8.4.    India pneumonia therapeutics market, by distribution channel, 2015 - 2026 (USD Million)
9.4.9.  Australia
9.4.9.1.    Australia pneumonia therapeutics market, by drug class, 2015 - 2026 (USD Million)
9.4.9.1.1.   Australia pneumonia therapeutics market, by antibacterial drugs, 2015 - 2026 (USD Million)
9.4.9.2.    Australia pneumonia therapeutics market, by age group, 2015 - 2026 (USD Million)
9.4.9.3.    Australia pneumonia therapeutics market, by infection type, 2015 - 2026 (USD Million)
9.4.9.4.    Australia pneumonia therapeutics market, by distribution channel, 2015 - 2026 (USD Million)
9.4.10.      Philippines
9.4.10.1.  Philippines pneumonia therapeutics market, by drug class, 2015 - 2026 (USD Million)
9.4.10.1.1. Philippines pneumonia therapeutics market, by antibacterial drugs, 2015 - 2026 (USD Million)
9.4.10.2.  Philippines pneumonia therapeutics market, by age group, 2015 - 2026 (USD Million)
9.4.10.3.  Philippines pneumonia therapeutics market, by infection type, 2015 - 2026 (USD Million)
9.4.10.4.  Philippines pneumonia therapeutics market, by distribution channel, 2015 - 2026 (USD Million)
9.5. Latin America
9.5.1.   Latin America pneumonia therapeutics market, by country, 2015 - 2026 (USD Million)
9.5.2.   Latin America pneumonia therapeutics market, by drug class, 2015 - 2026 (USD Million)
9.5.2.1.   Latin America pneumonia therapeutics market, by antibacterial drugs, 2015 - 2026 (USD Million)
9.5.3.    Latin America pneumonia therapeutics market, by age group, 2015 - 2026 (USD Million)
9.5.4.    Latin America pneumonia therapeutics market, by infection type, 2015 - 2026 (USD Million)
9.5.5.    Latin America pneumonia therapeutics market, by distribution channel, 2015 - 2026 (USD Million)
9.5.6.  Brazil
9.5.6.1.    Brazil pneumonia therapeutics market, by drug class, 2015 - 2026 (USD Million)
9.5.6.1.1.   Brazil pneumonia therapeutics market, by antibacterial drugs, 2015 - 2026 (USD Million)
9.5.6.2.    Brazil pneumonia therapeutics market, by age group, 2015 - 2026 (USD Million)
9.5.6.3.    Brazil pneumonia therapeutics market, by infection type, 2015 - 2026 (USD Million)
9.5.6.4.    Brazil pneumonia therapeutics market, by distribution channel, 2015 - 2026 (USD Million)
9.5.7.  Mexico
9.5.7.1.    Mexico pneumonia therapeutics market, by drug class, 2015 - 2026 (USD Million)
9.5.7.1.1.   Mexico pneumonia therapeutics market, by antibacterial drugs, 2015 - 2026 (USD Million)
9.5.7.2.    Mexico pneumonia therapeutics market, by age group, 2015 - 2026 (USD Million)
9.5.7.3.    Mexico pneumonia therapeutics market, by infection type, 2015 - 2026 (USD Million)
9.5.7.4.    Mexico pneumonia therapeutics market, by distribution channel, 2015 - 2026 (USD Million)
9.5.8.  Chile
9.5.8.1.    Chile pneumonia therapeutics market, by drug class, 2015 - 2026 (USD Million)
9.5.8.1.1.   Chile pneumonia therapeutics market, by antibacterial drugs, 2015 - 2026 (USD Million)
9.5.8.2.    Chile pneumonia therapeutics market, by age group, 2015 - 2026 (USD Million)
9.5.8.3.    Chile pneumonia therapeutics market, by infection type, 2015 - 2026 (USD Million)
9.5.8.4.    Chile pneumonia therapeutics market, by distribution channel, 2015 - 2026 (USD Million)
9.5.9.  Peru
9.5.9.1.    Peru pneumonia therapeutics market, by drug class, 2015 - 2026 (USD Million)
9.5.9.1.1.   Peru pneumonia therapeutics market, by antibacterial drugs, 2015 - 2026 (USD Million)
9.5.9.2.    Peru pneumonia therapeutics market, by age group, 2015 - 2026 (USD Million)
9.5.9.3.    Peru pneumonia therapeutics market, by infection type, 2015 - 2026 (USD Million)
9.5.9.4.    Peru pneumonia therapeutics market, by distribution channel, 2015 - 2026 (USD Million)
9.5.10.      Argentina
9.5.10.1.  Argentina pneumonia therapeutics market, by drug class, 2015 - 2026 (USD Million)
9.5.10.1.1. Argentina pneumonia therapeutics market, by antibacterial drugs, 2015 - 2026 (USD Million)
9.5.10.2.  Argentina pneumonia therapeutics market, by age group, 2015 - 2026 (USD Million)
9.5.10.3.  Argentina pneumonia therapeutics market, by infection type, 2015 - 2026 (USD Million)
9.5.10.4.  Argentina pneumonia therapeutics market, by distribution channel, 2015 - 2026 (USD Million)
9.6. MEA
9.6.1.   MEA pneumonia therapeutics market, by country, 2015 - 2026 (USD Million)
9.6.2.   MEA pneumonia therapeutics market, by drug class, 2015 - 2026 (USD Million)
9.6.2.1.   MEA pneumonia therapeutics market, by antibacterial drugs, 2015 - 2026 (USD Million)
9.6.3.    MEA pneumonia therapeutics market, by age group, 2015 - 2026 (USD Million)
9.6.4.    MEA pneumonia therapeutics market, by infection type, 2015 - 2026 (USD Million)
9.6.5.    MEA pneumonia therapeutics market, by distribution channel, 2015 - 2026 (USD Million)
9.6.6.  South Africa
9.6.6.1.    South Africa pneumonia therapeutics market, by drug class, 2015 - 2026 (USD Million)
9.6.6.1.1.   South Africa pneumonia therapeutics market, by antibacterial drugs, 2015 - 2026 (USD Million)
9.6.6.2.    South Africa pneumonia therapeutics market, by age group, 2015 - 2026 (USD Million)
9.6.6.3.    South Africa pneumonia therapeutics market, by infection type, 2015 - 2026 (USD Million)
9.6.6.4.    South Africa pneumonia therapeutics market, by distribution channel, 2015 - 2026 (USD Million)
9.6.7.  Saudi Arabia
9.6.7.1.    Saudi Arabia pneumonia therapeutics market, by drug class, 2015 - 2026 (USD Million)
9.6.7.1.1.   Saudi Arabia pneumonia therapeutics market, by antibacterial drugs, 2015 - 2026 (USD Million)
9.6.7.2.    Saudi Arabia pneumonia therapeutics market, by age group, 2015 - 2026 (USD Million)
9.6.7.3.    Saudi Arabia pneumonia therapeutics market, by infection type, 2015 - 2026 (USD Million)
9.6.7.4.    Saudi Arabia pneumonia therapeutics market, by distribution channel, 2015 - 2026 (USD Million)
9.6.8.  UAE
9.6.8.1.    UAE pneumonia therapeutics market, by drug class, 2015 - 2026 (USD Million)
9.6.8.1.1.   UAE pneumonia therapeutics market, by antibacterial drugs, 2015 - 2026 (USD Million)
9.6.8.2.    UAE pneumonia therapeutics market, by age group, 2015 - 2026 (USD Million)
9.6.8.3.    UAE pneumonia therapeutics market, by infection type, 2015 - 2026 (USD Million)
9.6.8.4.    UAE pneumonia therapeutics market, by distribution channel, 2015 - 2026 (USD Million)
9.6.9.  Israel
9.6.9.1.    Israel pneumonia therapeutics market, by drug class, 2015 - 2026 (USD Million)
9.6.9.1.1.   Israel pneumonia therapeutics market, by antibacterial drugs, 2015 - 2026 (USD Million)
9.6.9.2.    Israel pneumonia therapeutics market, by age group, 2015 - 2026 (USD Million)
9.6.9.3.    Israel pneumonia therapeutics market, by infection type, 2015 - 2026 (USD Million)
9.6.9.4.    Israel pneumonia therapeutics market, by distribution channel, 2015 - 2026 (USD Million)
Chapter 10.  Company Profiles
10.1.    Strategy Dashboard, 2019
10.2.    Abbott Laboratories
10.2.1.    Business Overview
10.2.2.    Financial data
10.2.3.    Product landscape
10.2.4.    Strategic outlook
10.2.5.    SWOT analysis
10.3.    Allergan, Inc.
10.3.1.    Business overview
10.3.2.    Financial data
10.3.3.    Product landscape
10.3.4.    Strategic outlook
10.3.5.    SWOT analysis
10.4.    AstraZeneca plc.
10.4.1.    Business overview
10.4.2.    Financial data
10.4.3.    Product landscape
10.4.4.    Strategic outlook
10.4.5.    SWOT analysis
10.5.    Bayer AG
10.5.1.    Business overview
10.5.2.    Financial Data
10.5.3.    Product landscape
10.5.4.    Strategic outlook
10.5.5.    SWOT analysis
10.6.    Cipla Inc.
10.6.1.    Business overview
10.6.2.    Financial data
10.6.3.    Product landscape
10.6.4.    SWOT analysis
10.7.    GlaxoSmithKline plc.
10.7.1.    Business overview
10.7.2.    Financial data
10.7.3.    Product landscape
10.7.4.    Strategic outlook
10.7.5.    SWOT analysis
10.8.    Lupin Pharmaceuticals, Inc.
10.8.1.    Business overview
10.8.2.    Financial data
10.8.3.    Product landscape
10.8.4.    SWOT analysis
10.9.    Merck & Co., Inc.
10.9.1.    Business overview
10.9.2.    Financial data
10.9.3.    Product landscape
10.9.4.    SWOT analysis
10.10.  Mylan N.V.
10.10.1.  Business overview
10.10.2.  Financial data
10.10.3.  Product landscape
10.10.4.  SWOT analysis
10.11.  Novartis AG
10.11.1.  Business overview
10.11.2.  Financial data
10.11.3.  Product landscape
10.11.4.  Strategic outlook
10.11.5.  SWOT analysis
10.12.  Pfizer Inc.
10.12.1.  Business overview
10.12.2.  Financial data
10.12.3.  Product landscape
10.13.  Sanofi S.A.
10.13.1.   Business overview
10.13.2.    Financial data
10.13.3.    Product landscape
10.13.4.    SWOT analysis

Data Tables TABLE 1. Pneumonia therapeutics industry 360 degree synopsis, 2015 - 2026 TABLE 2. Global pneumonia therapeutics market, 2015 - 2019 (USD Million) TABLE 3. Global pneumonia therapeutics market, 2020 - 2026 (USD Million) TABLE 4. Global pneumonia therapeutics market, by drug class, 2015 - 2019 (USD Million) TABLE 5. Global pneumonia therapeutics market, by drug class, 2020 - 2026 (USD Million) TABLE 6. Global pneumonia therapeutics market, by age group, 2015 - 2019 (USD Million) TABLE 7. Global pneumonia therapeutics market, by age group, 2020 - 2026 (USD Million) TABLE 8. Global pneumonia therapeutics market, by infection type, 2015 - 2019 (USD Million) TABLE 9. Global pneumonia therapeutics market, by infection type, 2020 - 2026 (USD Million) TABLE 10. Global pneumonia therapeutics market, by distribution channel, 2015 - 2019 (USD Million) TABLE 11. Global pneumonia therapeutics market, by distribution channel, 2020 - 2026 (USD Million) TABLE 12. Global pneumonia therapeutics market, by region, 2015 - 2019 (USD Million) TABLE 13. Global pneumonia therapeutics market, by region, 2020 - 2026 (USD Million) TABLE 14. Industry impact forces TABLE 15. Antibacterial drugs market, by region, 2015 - 2026, (USD Mn) TABLE 16. Antiviral drugs market, by region, 2015 - 2026, (USD Million) TABLE 17. Antifungal drugs market, by region, 2015 - 2026, (USD Million) TABLE 18. Pediatric market, by region, 2015 - 2026, (USD Million) TABLE 19. Adult market, by region, 2015 - 2026, (USD Million) TABLE 20. Geriatric market, by region, 2015 - 2026, (USD Million) TABLE 21. Hospital-acquired pneumonia (HAP) market by region, 2015 - 2026 (USD Million) TABLE 22. Community-acquired pneumonia (CAP) market by region, 2015 - 2026 (USD Million) TABLE 23. Ventilator-associated pneumonia (VAP) market by region, 2015 - 2026 (USD Million) TABLE 24. Hospital pharmacies market by region, 2015 - 2026 (USD Million) TABLE 25. Retail pharmacies market by region, 2015 - 2026 (USD Million) TABLE 26. Online pharmacies pneumonia therapeutics market, by region, 2015 - 2026, (USD Million) TABLE 27. North America pneumonia therapeutics market, by country, 2015 - 2026 (USD Million) TABLE 28. North America pneumonia therapeutics market, by drug class, 2015 - 2026 (USD Million) TABLE 29. North America pneumonia therapeutics market, by antibacterial drugs, 2015 - 2026 (USD Million) TABLE 30. North America pneumonia therapeutics market, by age group, 2015 - 2026 (USD Million) TABLE 31. North America pneumonia therapeutics market, by infection type, 2015 - 2026 (USD Mn) TABLE 32. North America pneumonia therapeutics market, by distribution channel, 2015 - 2026 (USD Mn) TABLE 33. U.S. pneumonia therapeutics market, by drug class, 2015 - 2026 (USD Million) TABLE 34. U.S. pneumonia therapeutics market, by antibacterial drugs, 2015 - 2026 (USD Million) TABLE 35. U.S. pneumonia therapeutics market, by age group, 2015 - 2026 (USD Million) TABLE 36. U.S. pneumonia therapeutics market, by infection type, 2015 - 2026 (USD Mn) TABLE 37. U.S. pneumonia therapeutics market, by distribution channel, 2015 - 2026 (USD Mn) TABLE 38. Canada pneumonia therapeutics market, by drug class, 2015 - 2026 (USD Million) TABLE 39. Canada pneumonia therapeutics market, by antibacterial drugs, 2015 - 2026 (USD Million) TABLE 40. Canada pneumonia therapeutics market, by age group, 2015 - 2026 (USD Million) TABLE 41. Canada pneumonia therapeutics market, by infection type, 2015 - 2026 (USD Mn) TABLE 42. Canada pneumonia therapeutics market, by distribution channel, 2015 - 2026 (USD Mn) TABLE 43. Europe pneumonia therapeutics market, by country, 2015 - 2026 (USD Million) TABLE 44. Europe pneumonia therapeutics market, by drug class, 2015 - 2026 (USD Million) TABLE 45. Europe pneumonia therapeutics market, by antibacterial drugs, 2015 - 2026 (USD Million) TABLE 46. Europe pneumonia therapeutics market, by age group, 2015 - 2026 (USD Million) TABLE 47. Europe pneumonia therapeutics market, by infection type, 2015 - 2026 (USD Mn) TABLE 48. Europe pneumonia therapeutics market, by distribution channel, 2015 - 2026 (USD Mn) TABLE 49. Germany pneumonia therapeutics market, by drug class, 2015 - 2026 (USD Million) TABLE 50. Germany pneumonia therapeutics market, by antibacterial drugs, 2015 - 2026 (USD Million) TABLE 51. Germany pneumonia therapeutics market, by age group, 2015 - 2026 (USD Million) TABLE 52. Germany pneumonia therapeutics market, by infection type, 2015 - 2026 (USD Mn) TABLE 53. Germany pneumonia therapeutics market, by distribution channel, 2015 - 2026 (USD Mn) TABLE 54. UK pneumonia therapeutics market, by drug class, 2015 - 2026 (USD Million) TABLE 55. UK pneumonia therapeutics market, by antibacterial drugs, 2015 - 2026 (USD Million) TABLE 56. UK pneumonia therapeutics market, by age group, 2015 - 2026 (USD Million) TABLE 57. UK pneumonia therapeutics market, by infection type, 2015 - 2026 (USD Mn) TABLE 58. UK pneumonia therapeutics market, by distribution channel, 2015 - 2026 (USD Mn) TABLE 59. Italy pneumonia therapeutics market, by drug class, 2015 - 2026 (USD Million) TABLE 60. Italy pneumonia therapeutics market, by antibacterial drugs, 2015 - 2026 (USD Million) TABLE 61. Italy pneumonia therapeutics market, by age group, 2015 - 2026 (USD Million) TABLE 62. Italy pneumonia therapeutics market, by infection type, 2015 - 2026 (USD Mn) TABLE 63. Italy pneumonia therapeutics market, by distribution channel, 2015 - 2026 (USD Mn) TABLE 64. Spain pneumonia therapeutics market, by drug class, 2015 - 2026 (USD Million) TABLE 65. Spain pneumonia therapeutics market, by antibacterial drugs, 2015 - 2026 (USD Million) TABLE 66. Spain pneumonia therapeutics market, by age group, 2015 - 2026 (USD Million) TABLE 67. Spain pneumonia therapeutics market, by infection type, 2015 - 2026 (USD Mn) TABLE 68. Spain pneumonia therapeutics market, by distribution channel, 2015 - 2026 (USD Mn) TABLE 69. France pneumonia therapeutics market, by drug class, 2015 - 2026 (USD Million) TABLE 70. France pneumonia therapeutics market, by antibacterial drugs, 2015 - 2026 (USD Million) TABLE 71. France pneumonia therapeutics market, by age group, 2015 - 2026 (USD Million) TABLE 72. France pneumonia therapeutics market, by infection type, 2015 - 2026 (USD Mn) TABLE 73. France pneumonia therapeutics market, by distribution channel, 2015 - 2026 (USD Mn) TABLE 74. Sweden pneumonia therapeutics market, by drug class, 2015 - 2026 (USD Million) TABLE 75. Sweden pneumonia therapeutics market, by antibacterial drugs, 2015 - 2026 (USD Million) TABLE 76. Sweden pneumonia therapeutics market, by age group, 2015 - 2026 (USD Million) TABLE 77. Sweden pneumonia therapeutics market, by infection type, 2015 - 2026 (USD Mn) TABLE 78. Sweden pneumonia therapeutics market, by distribution channel, 2015 - 2026 (USD Mn) TABLE 79. Finland pneumonia therapeutics market, by drug class, 2015 - 2026 (USD Million) TABLE 80. Finland pneumonia therapeutics market, by antibacterial drugs, 2015 - 2026 (USD Million) TABLE 81. Finland pneumonia therapeutics market, by age group, 2015 - 2026 (USD Million) TABLE 82. Finland pneumonia therapeutics market, by infection type, 2015 - 2026 (USD Mn) TABLE 83. Finland pneumonia therapeutics market, by distribution channel, 2015 - 2026 (USD Mn) TABLE 84. Russia pneumonia therapeutics market, by drug class, 2015 - 2026 (USD Million) TABLE 85. Russia pneumonia therapeutics market, by antibacterial drugs, 2015 - 2026 (USD Million) TABLE 86. Russia pneumonia therapeutics market, by age group, 2015 - 2026 (USD Million) TABLE 87. Russia pneumonia therapeutics market, by infection type, 2015 - 2026 (USD Mn) TABLE 88. Russia pneumonia therapeutics market, by distribution channel, 2015 - 2026 (USD Mn) TABLE 89. Asia Pacific pneumonia therapeutics market, by country, 2015 - 2026 (USD Million) TABLE 90. Asia Pacific pneumonia therapeutics market, by drug class, 2015 - 2026 (USD Million) TABLE 91. Asia Pacific pneumonia therapeutics market, by antibacterial drugs, 2015 - 2026 (USD Million) TABLE 92. Asia Pacific pneumonia therapeutics market, by age group, 2015 - 2026 (USD Million) TABLE 93. Asia Pacific pneumonia therapeutics market, by infection type, 2015 - 2026 (USD Mn) TABLE 94. Asia Pacific pneumonia therapeutics market, by sterility, 2015 - 2026 (USD Mn) TABLE 95. Asia Pacific pneumonia therapeutics market, by distribution channel, 2015 - 2026 (USD Mn) TABLE 96. China pneumonia therapeutics market, by drug class, 2015 - 2026 (USD Million) TABLE 97. China pneumonia therapeutics market, by antibacterial drugs, 2015 - 2026 (USD Million) TABLE 98. China pneumonia therapeutics market, by age group, 2015 - 2026 (USD Million) TABLE 99. China pneumonia therapeutics market, by infection type, 2015 - 2026 (USD Mn) TABLE 100. China pneumonia therapeutics market, by distribution channel, 2015 - 2026 (USD Mn) TABLE 101. India pneumonia therapeutics market, by drug class, 2015 - 2026 (USD Million) TABLE 102. India pneumonia therapeutics market, by antibacterial drugs, 2015 - 2026 (USD Million) TABLE 103. India pneumonia therapeutics market, by age group, 2015 - 2026 (USD Million) TABLE 104. India pneumonia therapeutics market, by infection type, 2015 - 2026 (USD Mn) TABLE 105. India pneumonia therapeutics market, by distribution channel, 2015 - 2026 (USD Mn) TABLE 106. Japan pneumonia therapeutics market, by drug class, 2015 - 2026 (USD Million) TABLE 107. Japan pneumonia therapeutics market, by antibacterial drugs, 2015 - 2026 (USD Million) TABLE 108. Japan pneumonia therapeutics market, by age group, 2015 - 2026 (USD Million) TABLE 109. Japan pneumonia therapeutics market, by infection type, 2015 - 2026 (USD Mn) TABLE 110. Japan pneumonia therapeutics market, by distribution channel, 2015 - 2026 (USD Mn) TABLE 111. Australia pneumonia therapeutics market, by drug class, 2015 - 2026 (USD Million) TABLE 112. Australia pneumonia therapeutics market, by antibacterial drugs, 2015 - 2026 (USD Million) TABLE 113. Australia pneumonia therapeutics market, by age group, 2015 - 2026 (USD Million) TABLE 114. Australia pneumonia therapeutics market, by infection type, 2015 - 2026 (USD Mn) TABLE 115. Australia pneumonia therapeutics market, by distribution channel, 2015 - 2026 (USD Mn) TABLE 116. Philippines pneumonia therapeutics market, by drug class, 2015 - 2026 (USD Million) TABLE 117. Philippines pneumonia therapeutics market, by antibacterial drugs, 2015 - 2026 (USD Million) TABLE 118. Philippines pneumonia therapeutics market, by age group, 2015 - 2026 (USD Million) TABLE 119. Philippines pneumonia therapeutics market, by infection type, 2015 - 2026 (USD Mn) TABLE 120. Philippines pneumonia therapeutics market, by distribution channel, 2015 - 2026 (USD Mn) TABLE 121. Latin America pneumonia therapeutics market, by country, 2015 - 2026 (USD Million) TABLE 122. Latin America pneumonia therapeutics market, by drug class, 2015 - 2026 (USD Million) TABLE 123. Latin America pneumonia therapeutics market, by antibacterial drugs, 2015 - 2026 (USD Million) TABLE 124. Latin America pneumonia therapeutics market, by age group, 2015 - 2026 (USD Million) TABLE 125. Latin America pneumonia therapeutics market, by infection type, 2015 - 2026 (USD Mn) TABLE 126. Latin America pneumonia therapeutics market, by distribution channel, 2015 - 2026 (USD Mn) TABLE 127. Argentina pneumonia therapeutics market, by drug class, 2015 - 2026 (USD Million) TABLE 128. Argentina pneumonia therapeutics market, by antibacterial drugs, 2015 - 2026 (USD Million) TABLE 129. Argentina pneumonia therapeutics market, by age group, 2015 - 2026 (USD Million) TABLE 130. Argentina pneumonia therapeutics market, by infection type, 2015 - 2026 (USD Mn) TABLE 131. Brazil pneumonia therapeutics market, by drug class, 2015 - 2026 (USD Million) TABLE 132. Brazil pneumonia therapeutics market, by antibacterial drugs, 2015 - 2026 (USD Million) TABLE 133. Brazil pneumonia therapeutics market, by age group, 2015 - 2026 (USD Million) TABLE 134. Brazil pneumonia therapeutics market, by infection type, 2015 - 2026 (USD Mn) TABLE 135. Brazil pneumonia therapeutics market, by distribution channel, 2015 - 2026 (USD Mn) TABLE 136. Mexico pneumonia therapeutics market, by drug class, 2015 - 2026 (USD Million) TABLE 137. Mexico pneumonia therapeutics market, by antibacterial drugs, 2015 - 2026 (USD Million) TABLE 138. Mexico pneumonia therapeutics market, by age group, 2015 - 2026 (USD Million) TABLE 139. Mexico pneumonia therapeutics market, by infection type, 2015 - 2026 (USD Mn) TABLE 140. Mexico pneumonia therapeutics market, by distribution channel, 2015 - 2026 (USD Mn) TABLE 141. Chile pneumonia therapeutics market, by drug class, 2015 - 2026 (USD Million) TABLE 142. Chile pneumonia therapeutics market, by antibacterial drugs, 2015 - 2026 (USD Million) TABLE 143. Chile pneumonia therapeutics market, by age group, 2015 - 2026 (USD Million) TABLE 144. Chile pneumonia therapeutics market, by infection type, 2015 - 2026 (USD Mn) TABLE 145. Chile pneumonia therapeutics market, by distribution channel, 2015 - 2026 (USD Mn) TABLE 146. Peru pneumonia therapeutics market, by drug class, 2015 - 2026 (USD Million) TABLE 147. Peru pneumonia therapeutics market, by antibacterial drugs, 2015 - 2026 (USD Million) TABLE 148. Peru pneumonia therapeutics market, by age group, 2015 - 2026 (USD Million) TABLE 149. Peru pneumonia therapeutics market, by infection type, 2015 - 2026 (USD Mn) TABLE 150. Peru pneumonia therapeutics market, by distribution channel, 2015 - 2026 (USD Mn) TABLE 151. Middle East & Africa pneumonia therapeutics market, by country, 2015 - 2026 (USD Million) TABLE 152. Middle East & Africa pneumonia therapeutics market, by drug class, 2015 - 2026 (USD Million) TABLE 153. Middle East & Africa pneumonia therapeutics market, by antibacterial drugs, 2015 - 2026 (USD Million) TABLE 154. Middle East & Africa pneumonia therapeutics market, by age group, 2015 - 2026 (USD Million) TABLE 155. Middle East & Africa pneumonia therapeutics market, by infection type, 2015 - 2026 (USD Mn) TABLE 156. Middle East & Africa pneumonia therapeutics market, by distribution channel, 2015 - 2026 (USD Mn) TABLE 157. South Africa pneumonia therapeutics market, by drug class, 2015 - 2026 (USD Million) TABLE 158. South Africa pneumonia therapeutics market, by antibacterial drugs, 2015 - 2026 (USD Million) TABLE 159. South Africa pneumonia therapeutics market, by age group, 2015 - 2026 (USD Million) TABLE 160. South Africa pneumonia therapeutics market, by infection type, 2015 - 2026 (USD Mn) TABLE 161. South Africa pneumonia therapeutics market, by distribution channel, 2015 - 2026 (USD Mn) TABLE 162. UAE pneumonia therapeutics market, by drug class, 2015 - 2026 (USD Million) TABLE 163. UAE pneumonia therapeutics market, by antibacterial drugs, 2015 - 2026 (USD Million) TABLE 164. UAE pneumonia therapeutics market, by age group, 2015 - 2026 (USD Million) TABLE 165. UAE pneumonia therapeutics market, by infection type, 2015 - 2026 (USD Mn) TABLE 166. UAE pneumonia therapeutics market, by distribution channel, 2015 - 2026 (USD Mn) TABLE 167. Saudi Arabia pneumonia therapeutics market, by drug class, 2015 - 2026 (USD Million) TABLE 168. Saudi Arabia pneumonia therapeutics market, by antibacterial drugs, 2015 - 2026 (USD Million) TABLE 169. Saudi Arabia pneumonia therapeutics market, by age group, 2015 - 2026 (USD Million) TABLE 170. Saudi Arabia pneumonia therapeutics market, by infection type, 2015 - 2026 (USD Mn) TABLE 171. Saudi Arabia pneumonia therapeutics market, by distribution channel, 2015 - 2026 (USD Mn) TABLE 172. Israel pneumonia therapeutics market, by drug class, 2015 - 2026 (USD Million) TABLE 173. Israel pneumonia therapeutics market, by antibacterial drugs, 2015 - 2026 (USD Million) TABLE 174. Israel pneumonia therapeutics market, by age group, 2015 - 2026 (USD Million) TABLE 175. Israel pneumonia therapeutics market, by infection type, 2015 - 2026 (USD Mn) TABLE 176. Israel pneumonia therapeutics market, by distribution channel, 2015 - 2026 (USD Mn) Charts & Figures FIG. 1 Industry segmentation FIG. 2 Global pneumonia therapeutics market, 2015 - 2026 (USD Million) FIG. 3 Growth potential analysis, by drug class FIG. 4 Growth potential analysis, by age group FIG. 5 Growth potential analysis, by infection type FIG. 6 Growth potential analysis, by distribution channel FIG. 7 Porter's Analysis FIG. 8 PESTEL Analysis FIG. 9 Key segment trends FIG. 10 Key segment trends FIG. 11 Key segment trends FIG. 12 Key segment trends FIG. 13 Key regional trends FIG. 14 Strategy Dashboard

Name*
Email ID*
Company*
Phone (With Country Code)*
What is/are your question(s)?:

New Pharmaceuticals and Healthcare Reports

Internal Neuromodulation Market Forecast 2025 | Global Report

Rising number of patients suffering from neurological disorders such as Parkinson’s, essential tremor, and primary dystonia is fueling the demand for internal neuromodulation procedures. Chronic back and leg pain associated with PVD (peripheral...

Gastrointestinal Cancer Treatment Market Size 2020-2025 | Growth Forecasts

As per credible projections, gastrointestinal cancer treatment industry is expected to register strong CAGR over 2019-2025. Rising adoption of unhealthy eating habits and increasing consumption of tobacco and alcohol have increased the pervasiveness ...

Topotecan Hydrochloride Market Trends and Research Insights by 2025

As per credible estimates, global topotecan hydrochloride market is poised to acquire commendable gains by the year 2025. Rising adoption of unhealthy and sedentary lifestyle has increased the pervasiveness of small cell lung cancer, ovarian cancer, ...

Flu Vaccine Market Share 2020-2025 | Global Industry Report

As per trusted estimates, global flu vaccine market will record substantial growth during 2020-2025. Increasing government initiatives to ensure the safety of the populace, minimal side-effects associated with influenza vaccines, improving efficacy o...

Healthcare Linen Market Size - Industry Trends Report 2025

According to reliable projections, global healthcare linen market is projected to record considerable growth during 2020-2025. Rising prevalence of various diseases including cardiovascular diseases, cancer, and arthritis along with increasing cases ...

Other Reports by Global Market Insights, Inc.

Online Powersports Market Size By Vehicle (All-Terrain Vehicle, Side By Side Vehicle, Personal Watercraft, Snowmobile, Heavyweight Motorcycle), Industry Analysis Report, Regional Outlook, Growth Potential, Competitive Market Share & Forecast, 2020 - 2026

The online power sports market is estimated to grow at a significant rate over the forecast time period owing to the increasing off-road leisure and recreational activities across the globe. With new product innovations, performance, and speed, the m...

Gum Fiber Market Size By Product (Gum Arabic, Guar Gum, Locust Bean Gum), By Application (Food [Frozen Foods, Confectionary, Beverages, Dairy], Oil & Gas, Mining & Construction, Textile, Pharmaceutical, Personal Care & Cosmetics), Industry Analysis Report, Regional, Growth Potential, Price Trends, Competitive Market Share & Forecast, 2020 - 2026

The gum fiber market is set to witness promising growth over the forthcoming time period owing to a rising product demand from a plethora of application avenues including offshore and onshore oil & gas industry, food industry, and mining & constructi...

Publisher: Global Market Insights, Inc.
Chat with us